An estimated 40 million people suffer from Intermittent Claudication disease worldwide. The disease represents Plaque deposits in primary artery limit the volume of blood supplies to legs, which results in cramps when walking. Pain is primarily observed in calves and occasionally in thighs and buttocks. Intermittent Claudication is often considered as a key symptom of the peripheral arterial disease. To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Intermittent Claudication pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Intermittent Claudication pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Intermittent Claudication pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Our reports have been used by over 10K customers, including:
“MT-102 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Cancer Cachexia in 7 Major Markets. A detailed picture of the MT-102 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period...
Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication, By Region, And Segment Forecasts, 2021 - 2028
Clinical Trials Market Growth & Trends
The global clinical...
Hospital Infection Therapeutics Market Report Overview Hospital Infection Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Hospital Infection Therapeutics market types and applications. It is a focused study on Hospital...
Sepsis Therapeutics Market Report Overview Sepsis Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Sepsis Therapeutics market types and applications. It is a focused study on Sepsis Therapeutics market space including global...
Uterine Cancer Therapeutics & Diagnostics Market Report Overview Uterine Cancer Therapeutics & Diagnostics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Uterine Cancer Therapeutics & Diagnostics market types and applications. It is...
“TTHX 1114 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Fuchs Endothelial Dystrophy in 7 Major Markets. A detailed picture of the TTHX 1114 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for...
“UBLITUXIMAB + UMBRALISIB - Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Diffuse Large B-Cell Lymphoma in 7 Major Markets. A detailed picture of the UBLITUXIMAB + UMBRALISIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the...
“ASN002 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Chronic Hand Eczema in 7 Major Markets. A detailed picture of the ASN002 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period...
Overview
“Phesgo - Drug Insight and Market Forecast - 2030” report outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Phesgo in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for...
“UBLITUXIMAB + UMBRALISIB - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Diffuse Large B-Cell Lymphoma in 7 Major Markets. A detailed picture of the UBLITUXIMAB + UMBRALISIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the...
Lymphoma
Therapy
Research And Development
Clinical Trial
Europe
Japan
World
Spain
France
Germany
Italy
United Kingdom
United States
Health Expenditure
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.